title: Private and public coverage policies for rituximab in the treatment of immunobullous disease in the United States.
authors.affiliation: Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Florida.
authors.forename: Romi
authors.initials: R
authors.lastname: Bloom
authors.affiliation: Department of Internal Medicine, MacNeal Hospital, Berwyn, Illinois. Electronic address: KAmber@med.miami.edu.
authors.forename: Kyle T
authors.initials: KT
authors.lastname: Amber
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000191:economics* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000191:economics / Q000276:immunology; D016208:Databases, Factual; D016527:Drug Costs; D005260:Female; D017048:Health Care Costs; D006801:Humans; D019458:Insurance Coverage / Q000191:economics* / Q000706:statistics & numerical data; D007348:Insurance, Health / Q000191:economics / Q000706:statistics & numerical data; D008297:Male; D020380:Needs Assessment; D011050:Policy Making; D017149:Private Sector / Q000191:economics* / Q000706:statistics & numerical data; D000069283:Rituximab; D012872:Skin Diseases, Vesiculobullous / Q000188:drug therapy* / Q000191:economics / Q000276:immunology; D014481:United States
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab